The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | The limitations of current standards of care for Hodgkin lymphoma
Jonathan Friedberg, MD MMSc, Wilmot Cancer Center, University of Rochester, Rochester, NY, discusses the limitations of current standards of care for Hodgkin lymphoma. Prof. Friedberg shares that patients usually respond well to chemotherapy, but for advanced-stage disease, nearly 20% of patients do not respond. Ultimately, almost 30% of patients will need additional treatment. The efforts in the long term aim to increase the number of cured patients and decrease the need for salvage therapy. To address the issue of toxicities, the substitution of standard agents like bleomycin with brentuximab shows a considerable improvement in toxicity rates. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
